Featured Research

from universities, journals, and other organizations

Biotechnology Research To Grow From Embryonic Start

Date:
September 15, 2000
Source:
Adelaide University
Summary:
A South Australian Company is importing human embryonic stem cells into Australia to use in biotechnology research at Adelaide University. The process, patented by Bresagen, holds promise in the treatment of Alzheimer's, spinal cord injury, diabetes and a range of other diseases associated with cell dysfunction.

The Adelaide-based biotechnology company, BresaGen, expects to receive human embryonic stem (ES) cells in the near future from the University of Wisconsin, USA. The cells are intended for use in the BresaGen Cell Therapy Programme which is conducted in the Department of Biochemistry at Adelaide University under the scientific direction of Professor Peter Rathjen.

Related Articles


Stem cells are embryonic cells, among the first to appear as a fertilised egg develops. They have the ability to develop into most of the specialised cells in the human body including blood, skin, muscle and nerve cells They also have the capacity to divide and proliferate indefinitely in culture.

Scientists can use these two unique properties of stem cells to produce seemingly limitless supplies of most human cell types from stem cells, paving the way for the treatment of diseases by cell replacement. In fact, cell therapy has the potential to treat any disease that is associated with cell dysfunction or damage, including stroke, diabetes, Alzheimer’s and Parkinson’s diseases, heart attack, spinal cord injury, cancer, and AIDS.

Parkinson’s disease provides a model of how such treatment might occur. The disease is caused by dysfunctional nerve cells in a particular area of the brain. Using cell therapy, these faulty cells could be replaced with healthy, stem cell-derived nerve cells.

"Scientists in the Cell Therapy Programme have been able to produce nerve, muscle and blood cells from mouse ES cells and would like to demonstrate the same transitions using human ES cells," said Dr Paul Tolstoshev. "BresaGen is focusing on developing cell-based therapies for Parkinson’s Disease and genetic diseases of the bone marrow, using the mouse and rat as model systems," he said.The most useful population of human stem cells for therapeutic purposes are the embryonic stem cells. In December 1998, two USA research teams announced the isolation and stable regeneration of human ES cells in culture. Despite the great promise offered by these cells, their source and acquisition raised important ethical questions.

These human ES cell lines have come from two different sources. One line was isolated from human foetal tissue obtained from terminated pregnancies, the other was obtained from surplus early-stage human embryos donated by individuals undergoing IVF treatment. It is cells from this second line that Bresagen will use.

Despite the fact that both tissue sources were donated with the informed consent of the donors, the destruction of embryos for stem cell isolation has attracted criticism from some pro-life, religious and bioethics groups. The central ethical argument hinges on the status of an embryo. "The early-stage embryos used for the isolation of human stem cells are no more than six days old and are invisible to the naked eye," said Dr Tolstoshev, Manager of the Cell Reprogramming Division at BresaGen. "Furthermore, these embryos are composed of around 100-200 unspecialised cells and contain no specialised cell types such as those that make up the central nervous system, including the brain," he said.

The isolation of stem cells from human embryos is legally difficult in Australia, but researchers here are permitted to import cells that have been legally isolated in another country. A research group led by Professor Alan Trounson at the Monash Institute of Reproduction and Development recently obtained human ES cells in this way. Once isolated, stem cells can be handled in the laboratory under guidelines similar to those governing other human cell types.

Because stem cells at present must be harvested from embryonic tissue, there is the possibility of an immune reaction when they are implanted into a recipient; an outcome associated with many organ and tissue transplants. There is also difficulty in obtaining sufficient donor cells. Both problems could be overcome if stem cells could, instead, be harvested from the patient that they are used to treat.

Dr Tolstoshev sees the possibility that stem cell technology may develop to this point, at which embryonic cells will not be required. "There is strong evidence for stem cell populations in adult tissues such as skin, blood and brain," he said. "These may have the potential to form many of the specialised cells in the body, but they are very difficult to isolate and grow using current technologies."However, there are strong indications that researchers may be able to reprogram normal adult cells to form cells of an earlier developmental stage, possibly even to the ES cell stage.

"If we can develop such technology we can avoid the moral and ethical issues," said Dr Tolstoshev, "but it is critical at this stage that we have access to human embryonic stem cells so that we can study the complex biology involved and assess their potential for cell therapy applications."

BresaGen is attempting to derive stem cells from normal adult cells, which would overcome the ethical issues associated with the isolation of embryonic stem cells and provide an immune-compatible source of cells for therapy. The research is following two separate paths.In the first, adult cells could be coaxed to form stem cell populations by manipulating the cell culture conditions. The alternative route would involve using ‘nuclear transfer technology’, which was used to produce Dolly, the world’s first cloned sheep. This could be done by fusing an adult cell with either an egg cell, or with an ES cell, that has had its genetic material removed, and then using the resulting stem cells to derive specialised cell types for therapeutic applications.

Although nuclear transfer technology has been used to clone several species including sheep, pigs, goats, cows, and mice, there is no evidence to suggest that the technology can be extended to humans. Furthermore, there is a world-wide ban on human reproductive cloning, and the majority of scientists, government authorities and bioethicists agree that human cloning would offer no benefit to society.

A cell that is recently fertilised is termed totipotent, meaning that it has the unlimited capacity to develop into all postembryonic tissues. As the cell develops and divides repeatedly, this potential is briefly retained. Identical twins develop at the stage when the initial egg has divided into two cells, each of which forms a person.

Normally, however, the divisions occur repeatedly within the single embryo, and as they increase in number, some of the developmental potential of the cells is lost. Once the developing embryo has formed a hollow ball of cells, a cluster of them inside are termed pluripotent. These pluripotent cells can not form a placenta and its supporting tissues, so they can not develop into a complete organism, but they can form virtually all the tissues of the human body.

Several private companies own patents protecting different aspects of stem cell therapy. Geron, a biotechnology company based in California, owns substantial Intellectual Property relating to the identification and use of human pluripotent cells, and methods for the isolation and regeneration of human embryonic stem cells.

It is likely that other complementary technologies will also be required to develop stem cell-based therapies. BresaGen has exclusive rights to a patent application which claims an intermediate cell type (EPL cell) that shares most of the characteristics of embryonic stem cells, but can be more easily coaxed to form specific cell types. The therapeutic uses of this cell type and its derivatives are also claimed in the application. The patent application was filed by Adelaide University and was acquired by BresaGen in 1999.

Photos at: http://www.adelaide.edu.au/PR/media_photos/

Contact:
Dr Paul Tolstoshev, Ph: (618) 8234 2660, email ptostoshev@bresagen.com.au

Prof Peter Rathjen, Ph: (618) 8303 5354, email: peter.rathjen@adelaide.edu.au

--------------------
Dr Rob Morrison, Media Unit, Adelaide University
Ph: (618) 8303 3490, email rob.morrison@adelaide.edu.au


Story Source:

The above story is based on materials provided by Adelaide University. Note: Materials may be edited for content and length.


Cite This Page:

Adelaide University. "Biotechnology Research To Grow From Embryonic Start." ScienceDaily. ScienceDaily, 15 September 2000. <www.sciencedaily.com/releases/2000/09/000905211456.htm>.
Adelaide University. (2000, September 15). Biotechnology Research To Grow From Embryonic Start. ScienceDaily. Retrieved November 20, 2014 from www.sciencedaily.com/releases/2000/09/000905211456.htm
Adelaide University. "Biotechnology Research To Grow From Embryonic Start." ScienceDaily. www.sciencedaily.com/releases/2000/09/000905211456.htm (accessed November 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Obesity Costs Almost As Much As War And Terrorism

Obesity Costs Almost As Much As War And Terrorism

Newsy (Nov. 20, 2014) The newest estimate of the cost of obesity is pretty jarring — $2 trillion. But how did researchers get to that number? Video provided by Newsy
Powered by NewsLook.com
Ebola Crisis Affecting US Adoptions

Ebola Crisis Affecting US Adoptions

AP (Nov. 20, 2014) The Sanborn family had hoped they'd be able to bring home their 5-year-old adopted son from Liberia by now. But Ebola has forced them to wait. The boy is just one of thousands of orphans in West Africa who've been impacted by the deadly virus. (Nov. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins